Although these results do indicate a potential therapeutic benefit of targeting IL-17A, the heterogeneity of TH17 cells makes it difficult to conclude their exact function in human CRC and further research is needed before initiating clinical trials. Here, IL17A is linked to colorectal carcinoma.